<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00664014</url>
  </required_header>
  <id_info>
    <org_study_id>156-07-802-01</org_study_id>
    <nct_id>NCT00664014</nct_id>
  </id_info>
  <brief_title>A Phase 2 Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia</brief_title>
  <official_title>Randomized, Double-blind, Multicenter, Placebo-controlled (Standard Therapy + Placebo), Phase 2 Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Beijing Research Institute</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Otsuka Beijing Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, multicenter, placebo-controlled (standard therapy +
      placebo), phase 2 efficacy and safety study of the Tolvaptan tablets in treatment of patients
      with non-hypovolemic non-acute hyponatremia arising from a variety of etiologies. 240 (120 in
      each group) patients are to be enrolled randomly into Tolvaptan group or placebo group.
      Subjects in Tolvaptan group will receive standard therapy + Tolvaptan (15-60mg/day), while
      those in control group receiving standard therapy + placebo. The starting dose of tolvaptan
      is 15mg and it could be titrated up to 30mg and then,if necessary, to the maximum of 60mg
      according to a certain titration scheme based on patients' response of serum sodium level.
      The study includes a 2-day screening period from day -2 to day -1, 7-day inpatient study
      treatment (day 1 to day 7 ). After study treatment, subjects will be Followed-up on safety
      events on day 14 - 16. The Primary Efficacy Variable is the change of serum sodium from
      baseline. For patients with Congestive Heart Failure (CHF) or hepatic cirrhosis, change of
      body weight, fluid balance and symptoms improvement of CHF and hepatic edema will be assessed
      as secondary efficacy variables.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of average daily Area Under the Curve (AUC) of serum sodium by day 4 and 7 comparing with baseline serum sodium level within the double-blind therapy period.</measure>
    <time_frame>4 and 7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>For CHF and hepatic edema patients, improvement of symptoms and relevant physical examination measures or ultrasound test findings . Other secondary efficacy variables on blood serum sodium, fluid balance or body weight change.</measure>
    <time_frame>4 or 7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Hypovolemic Hyponatremia</condition>
  <arm_group>
    <arm_group_label>Tolvaptan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolvaptan</intervention_name>
    <description>Tablet;15mg/tab;15/30/60mg/day for 7days Plus conventional therapy according to each patient's underlying disease, such as congestive heart failure, hepatic cirrhosis and SIADH or others.</description>
    <arm_group_label>Tolvaptan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo plus conventional therapy according to each patient's underlying disease, such as congestive heart failure, hepatic cirrhosis and SIADH or others.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent.

          2. Age:18～75 (when informed consent is obtained)，male or female.

          3. Non-hypovolemic and non acute hyponatremia with a Serum sodium &lt; 135mEq/L before
             randomization. (main underlying diseases include CHF, hepatic cirrhosis with edema,
             SIADH and others)

          4. In-patient subjects.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wenling Zhu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Feng Gu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jidong Jia</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Friendship Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiology, the Third Xiangya Hospital, Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Human</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Cardiology, Xiangya Hospital, Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology, Jilin University Second Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jinlin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrinology, West China Hospital Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology / Endocrinology, Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology / Hepatology, Beijing Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology/Endocrinology/Infection, Beijing University First Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrinology, No. 301 hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hepatology, Beijing Renmin Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hepatology/Endocrinology, Chongqing Medical University Second Hospital</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hepatology / Endocrinology, Shanghai Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology, Tianjin Medical University Second Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrinology, Tianjin General Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2008</study_first_submitted>
  <study_first_submitted_qc>April 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2008</study_first_posted>
  <last_update_submitted>March 5, 2010</last_update_submitted>
  <last_update_submitted_qc>March 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Yong Jin / Project Manager</name_title>
    <organization>Otsuka Beijing Research Institute</organization>
  </responsible_party>
  <keyword>hyponatremia</keyword>
  <keyword>Non-acute and non hypovolemic hyponatremia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyponatremia</mesh_term>
    <mesh_term>Hypovolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolvaptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

